I-Sovaldi (i-sofosbuvir) iyinombolo ye-nucleotide ye-polymerase ye-inhibitor yeklasi yeziyobisi esetyenziswa ngokudibanisa unyango lwe-anti-infiratory for the treatment of hepatitis C (HCV) . U-Sovaldi usebenza ngokuthintela i-enzyme eyenziwa yi-HCV ukuphinda i-RNA yayo, ngokuphazamisa ngokuphumelelayo isigaba kwi-lifecycle virus.
I-Sovaldi yavunywa ngoDisemba ka-2013 yi-US Food and Drug Administration (FDA) ekusebenziseni abantu abadala kwiminyaka eyi-18 okanye ngaphezulu kunye ne-HCV ye-genotypes 1, 2, 3 no-4, kunye ne- hepatocellular carcinoma (uhlobo oluqhelekileyo lwesifo somhlaza) kunye nabantu abane- HIV kunye ne- HCV yokusulela.
I-Sovaldi ivunyiwe ukuba isebenziswe kwizigulane zangaphambili ezingaphatulwanga (unyango-naïve), kwakunye nalabo abanengxenye okanye abangenayo impendulo kwi-HCV ngaphambi kokunyanga.
Uphando lwezonyango luye lwabonisa ukuba izinga lokunyanga kwizigulane zonyango kwi-Sovaldi-based regimen liphakathi kwe-82% ne-96%.
Isistim
I-tablet enye ye-400 mg ithathwa imihla ngemihla okanye ngaphandle kokutya. Iipilisi zeSovaldi ziluphuzi kunye nefilimu-yambethe, kunye ne "GSI" emacaleni kwelinye icala kunye "7977" kwelinye.
Ukucetyiswa kweengcebiso
I-Sovaldi imiselwe ukuba isetyenziswe ngonyango kunye nerbavirin ; kunye ne-intergyon ye-pegylated (i-peg-interferon) + i-ribavirin; okanye ngeDadlinza (daclatasvir) . I-Sovaldi akumele isetyenziswe njenge-monotherapy.
Ezi zilandelayo zicetyiswa unyango:
- I-Genotype 1 okanye 4: I-Sovaldi + i-peg-interferon + ribavirin iiveki ezili-12
- I-Genotype 2: I-Sovaldi + ribavirin iiveki ezili-12.
- I-Genotype 3: I-Sovaldi + ribavirin iiveki ezingama-24 OKANYE u-Sovaldi + Daklinza (daclatasvir) kwiiveki eziyi-12
Kwizigulane ezine-genotype 1 ezingenakufaneleka kwi-interferon okanye i-interferon-engavumiyo, kuyacetyiswa ukuba udibaniso lweSovaldi + ribavirin lubekwe iiveki ezingama-24.
Kuzo naziphi na izigulane ezilindele ukufakelwa kwesibindi, imirhumo echazwe apha ngasentla kufuneka imiselwe kwiiveki ezingama-48 okanye kude kube yinto yokutshintshwa, nantoni na kuqala.
Iziphumo eziPhakathi
Imiphumo echaphazelekayo ehambelana nokusetyenziswa kweSovaldi + ribavirin (oko kukuthi, okwenzeka kwi-20% okanye ngaphantsi kwezigulane) kukuba:
- Ukukhathala
- Intloko
- I sizathu
Iziphumo eziqhelekileyo ezichazwe kwizigulane ezisebenzisa iSovaldi + ribavirin + peg-interferon zi:
- Ukukhathala
- Intloko
- I sizathu
- Ukungabikho
- IAnemia
Ngaphandle kwe-anemia kunye ne-neutropenia, uninzi lweziphumo ezichaphazelekayo ezinxulumene nokusetyenziswa kweSovaldi zibhekwa njengobumnene okanye obude (iBakala 1).
Kuphando lweklinikhi, i-1% okanye ngaphantsi kwezigulane kwiSovaldi + ribavirin yaphelisa unyango ngaphambi kwexesha ngenxa yemiphumo emibi. Iziganeko zanda kwi-11% kwizigulane kwiSovaldi + ribavirin + peg-interferon.
Ukusebenzisana kweziyobisi
Oku kulandelayo kufuneka kuphetshwe xa usebenzisa iSovaldi:
- I-Rifampin-based based anti-tuberculosis amayeza: Mycobutin, Rifater, Rifamate, Rimactane, Rifadin, Priftin
- Anticonvulsants: Tegretol, Dilantin, Trileptal, phenobarbital
- ISt John's Wort
Kwiigulane ezine- HIV , iSovaldi akufanele ilawulwe ngokubambisana kunye ne-Aptivus (tipranavir) okanye i-Norvir (ritonavir) njengoko le protase inhibitor ye- antiretrovirals yeklasi inganciphisa umxube we-Sovaldi.
Ukungqinelana
I-Sovaldi iphikisana nokusetyenziswa ngexesha lokukhulelwa okanye kumadoda abathandana nabo abakhulelweyo njengoko uphando lwezilwanyana luye lwaphakamisa umngcipheko wokuba lulele okanye lufe.
Kunconywa ukuba bonke abafazi abaneminyaka engama-50 ubudala bahlolwe rhoqo ngenyanga ngokukhulelwa ngexesha loqeqesho. Kukwacetyiswa ukuba isigulane kunye nomlingani wakhe wesilisa banikezelwe ubuncinane iindlela ezimbini ezingekho-hormonal zokukhulelwa kwezilwanyana kwaye zisetyenziswe ngexesha lokunyanga kunye neenyanga ezintandathu emva koko.
Umthombo:
Manns, M. and Cornberg, M. "Sofosbuvir: isikhonkwane sokugqibela ebhokisini ye-hepatitis C?" Lancet. Matshi 15, 2013; 13 (5): 378-379.